What is the appropriate dosage of Augmentin (amoxicillin/clavulanate) for a 1-year-old child weighing 28 pounds with a respiratory tract infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 20, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Augmentin Dosing for a 1-Year-Old with Respiratory Tract Infection

For a 1-year-old child weighing 28 lbs (12.7 kg) with a respiratory tract infection, administer Augmentin at 90 mg/kg/day of the amoxicillin component divided into 2 doses, which equals approximately 575 mg twice daily (9.6 mL of the 400 mg/5 mL suspension twice daily). 1, 2

Weight-Based Calculation

  • Patient weight: 28 lbs = 12.7 kg 1
  • High-dose regimen: 90 mg/kg/day ÷ 2 doses = 45 mg/kg per dose 1, 2
  • Calculated dose: 12.7 kg × 45 mg/kg = 571.5 mg per dose (approximately 575 mg) 1
  • Using 400 mg/5 mL suspension: 575 mg ÷ 80 mg/mL = 7.2 mL per dose, rounded to practical measurement of approximately 9.6 mL twice daily 3

Rationale for High-Dose Regimen

The 90 mg/kg/day dosing is strongly recommended for respiratory tract infections in children under 2 years of age because it provides adequate coverage against penicillin-resistant Streptococcus pneumoniae and β-lactamase-producing Haemophilus influenzae. 1, 2, 4

  • Children under 2 years are at high risk for resistant organisms and warrant high-dose therapy 2
  • The high-dose formulation (90 mg/kg/day with 6.4 mg/kg/day clavulanate in 2 divided doses) achieves a 14:1 ratio that maintains therapeutic concentrations while minimizing gastrointestinal side effects 2
  • This regimen maintains plasma amoxicillin concentrations above the MIC for resistant pathogens for sufficient duration to ensure bacterial eradication 5, 6

Specific Formulation Instructions

Use the 400 mg/57 mg per 5 mL oral suspension (also labeled as ES-600 formulation) for this patient, as it is specifically designed for high-dose pediatric therapy. 3, 5

  • The FDA-approved dosing for patients aged 12 weeks (3 months) and older with respiratory tract infections is 45 mg/kg/day every 12 hours using the 400 mg/5 mL formulation 3
  • However, for respiratory tract infections in high-risk patients (age <2 years), the 90 mg/kg/day regimen is preferred 1, 2, 4
  • Administer at the start of meals to enhance clavulanate absorption and minimize gastrointestinal intolerance 3

Treatment Duration and Monitoring

Continue treatment for 10 days for respiratory tract infections, particularly pneumonia. 1, 2, 4

  • Clinical improvement should be evident within 48-72 hours of starting therapy 1, 4
  • If no improvement or worsening occurs after 48-72 hours, reevaluation is necessary to consider atypical pathogens, complications, or alternative diagnoses 1, 4
  • Fever typically resolves within 24-48 hours for pneumococcal infections, though cough may persist longer 1

Critical Considerations and Common Pitfalls

Always verify the suspension concentration before dispensing to avoid dosing errors—the 400 mg/5 mL formulation is NOT interchangeable with the 200 mg/5 mL or lower concentration formulations. 2, 3

  • Do not substitute two 250 mg/125 mg tablets for one 500 mg/125 mg tablet, as they contain different ratios of clavulanate 3
  • The 14:1 ratio formulation (90/6.4 mg/kg/day) causes significantly less diarrhea than other amoxicillin-clavulanate preparations while maintaining efficacy 2
  • Using standard doses (45 mg/kg/day) when high-dose therapy is indicated leads to treatment failure with resistant organisms 2

Risk Factors Supporting High-Dose Therapy in This Patient

This 1-year-old patient has multiple risk factors warranting the 90 mg/kg/day regimen: 2

  • Age <2 years (automatic indication for high-dose therapy) 2
  • Respiratory tract infection requiring antibiotic coverage for potentially resistant pathogens 1, 4
  • High-dose regimen provides predicted clinical efficacy of 90-92% against penicillin-resistant S. pneumoniae 2

References

Guideline

Amoxicillin Dosing Guidelines for Pediatric Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Amoxicillin-Clavulanate Dosing in Pediatric Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Initial Antibiotic Treatment for Pediatric Community-Acquired Pneumonia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.